FolioStart free

Medicine · Literature

Research papers on GLP-1 drugs and weight loss

Recent and highly-cited academic work on glp-1 drugs and weight loss, gathered from Semantic Scholar, CrossRef and OpenAlex.

Search all 200M+ papers on this topic, free →Or track new glp-1 drugs and weight loss papers automatically as they publish

  1. The Discovery and Development of Liraglutide and Semaglutide

    Lotte Bjerre Knudsen, Jesper F. Lau · 2019 · Frontiers in Endocrinology · 963 citations

    The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects on glycemic control and body weight regulation, led to efforts to extend its half-life and make it therapeutically effective in people with type 2 diabetes (T2D). The development of short- and then long-acting GLP-1 receptor agonists (GLP-1RAs) followed. Our article charts the discovery and development of the long-acting GLP-1 analogs liraglutide and, subsequently, semaglutide. We examine the chemistry employed in designing liraglutide and semaglutide, the human and non-human studies used to investigate their cellular targets and pharmacological effects, and ongoing investigations into new applicatio

    Save this paper

  2. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity

    Patricia J. Rodriguez, Brianna M Goodwin Cartwright, Samuel Gratzl, et al. · 2024 · JAMA Internal Medicine · 329 citations

    Importance: Although tirzepatide and semaglutide were shown to reduce weight in randomized clinical trials, data from head-to-head comparisons in populations with overweight or obesity are not yet available. Objective: To compare on-treatment weight loss and rates of gastrointestinal adverse events (AEs) among adults with overweight or obesity receiving tirzepatide or semaglutide labeled for type 2 diabetes (T2D) in a clinical setting. Design, Setting, and Participants: In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data linked to dispensing information from

    Save this paper

  3. Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management

    Gurdeep Singh, Matthew Krauthamer, Meghan Bjalme-Evans · 2021 · Journal of Investigative Medicine · 240 citations

    Obesity is a growing epidemic within the USA. Because weight gain is associated with an increased risk of developing life-threatening comorbidities, such as hypertension or type 2 diabetes, there is great interest in developing non-invasive pharmacotherapeutics to help combat obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic medications that have shown promise in encouraging glycemic control and promoting weight loss in patients with or without type 2 diabetes. This literature review summarizes and discusses the weight loss results from the SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes), PIONEER (Peptide Innovation for Early

    Save this paper

  5. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity

    Fatima Quddos, Zachary Hubshman, Allison N. Tegge, et al. · 2023 · Scientific Reports · 150 citations

    Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has shown to effectively reduce the consumption of alcohol in animal models but no reports exist on the latter. In this report, we conducted two studies. In the first study, we conducted an analysis of abundant social media texts. Specifically, a machine-learning based attribution mapping of ~ 68,250 posts related to GLP-1 or GLP-1/GIP agonists on the Reddit platform. Secondly, we recruited participants (n = 153; current alcohol drinkers; BMI ≥ 30

    Save this paper

  6. Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment

    Rui Salvador, Carla Maria Sanfins Guimarães Moutinho, Carla Sousa, et al. · 2025 · Pharmaceuticals · 42 citations

    This review addresses the role of semaglutide (SMG), a GLP-1 receptor agonist, in the treatment of obesity and its related comorbidities. Originally developed for type 2 diabetes (DM2), SMG has shown significant efficacy in weight reduction, with superior results compared to other treatments in the same class. Its effects include appetite suppression, increased satiety, and improvements in cardiovascular, renal, and metabolic parameters. Studies such as SUSTAIN, PIONEER, and STEP highlight its superiority compared to other GLP-1 receptor agonists and anti-obesity drugs. The oral formulation showed promising initial results, with higher doses (50 mg) showing weight losses comparable to those

    Save this paper

  10. 847-P: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

    JINZI JASON WU, CHENGFEI WU · 2025 · Diabetes · 2 citations

    Introduction and Objective: ASC47 (selective THR-β agonist) is an adipose-targeted, once-monthly subcutaneously (SQ) injected, muscle-preserving weight loss drug candidate for the treatment of obesity, discovered and developed in-house at Ascletis. This study in diet-induced obese (DIO) mice demonstrated a powerful synergy in weight loss and muscle preservation when combining ASC47 and semaglutide. Methods: C57BL/6J mice were fed a high-fat diet for 16 weeks and received different treatments for 28 days. Body weight and food intake were recorded daily. Body composition was assessed by EchoMRI weekly. Results: ASC47 low dose combination 1 demonstrated superior weight loss compared to semaglut

    Save this paper

  14. Session IA: Biology Presentation 3 - Beyond Weight Loss: The Effects of the GLP-1 Agonist, Semaglutide, on Weight Care, Type II Diabetes Management, and Cardiac Function in Obese Patients

    Smith, Amber · 2025 · Digital Commons - Gardner-Webb University (Gardner–Webb University)

    Determining whether the drug Semaglutide, also known as Ozempic or Wegovy, is not only an effective treatment for weight loss, but also for management of type II diabetes and obesity-related heart failure, such as adverse cardiac remodeling and left atrial volume increase.

    Save this paper

  17. 1050-P: Revolutionary GLP-1 Weight Loss Medicine Semaglutide—To Cover or Not to Cover?

    WENHAO LU, AMELIA XIE, YIMEI YOU · 2025 · Diabetes

    Introduction and Objective: We created a data-driven prioritizing system to determine which groups of patients benefit most by insurance coverage of Semaglutide based on short- and long-term cost effectiveness in managing obesity and related chronic diseases. This prioritizing model will enhance societal health outcomes and promote equitable access compared to current affordability-based coverage models. Methods: This study uses a retrospective cohort design with CDC survey data from 2019-2023. We analyzed the prevalence of obesity-related diseases across different weight groups to simulate the potential effectiveness of Semaglutide in managing chronic conditions. Correlation analysis was us

    Save this paper

Write your paper with these sources

Folio is the integrity-first research workspace: search 200M+ papers, save sources, and write with citations that format themselves. Free for students and researchers.

Start writing free →